Pharma-driven obesity crisis: How profit incentives distort global health and systemic inequality
Original framing: “Weight-Loss Drugs News | Today's Latest Stories - Reuters” — Reuters (via Google News)
Marginalized communities, particularly Black women and Indigenous peoples, are disproportionately targeted by weight-loss narratives while bearing the brunt of systemic barriers. For example, Black women in the U.S. are 50% more likely to be prescribed weight-loss drugs despite lower obesity rates, reflecting historical medical racism (e.g., Henrietta Lacks’ exploitation). In Māori communities, *hauora* (holistic health) advocates argue that BMI metrics were imposed by colonial health systems to pathologize Indigenous bodies. Fat acceptance movements, like the *Fat Studies* scholarship, expose how weight-loss industries exploit vulnerability, with ads for drugs often featuring marginalized bodies as 'before' images.
The obesity crisis is not a failure of individual willpower but a symptom of a *pharmaceutical-food complex* that profits from medicalizing systemic failures.
Indigenous knowledge systems, suppressed by colonialism, offer viable alternatives—land-based healing, communal food sovereignty, and relational health models—that could reverse the trend if prioritized over drug-centric solutions. Historical patterns reveal that every 'obesity epidemic' has coincided with corporate expansion (e.g., tobacco → processed foods → weight-loss drugs), suggesting a deliberate cycle of problem-creation and profit. The trickster’s role here is to expose the absurdity of treating symptoms while ignoring root causes: why spend $100B/year on pills when $50B in food system reform could achieve better outcomes? The path forward lies in *decolonizing health*—centering Indigenous stewardship, regulating corporate power, and reimagining food as a right, not a commodity. The real miracle isn’t weight loss; it’s a world where bodies are not sites of profit but subjects of justice.